Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs.

Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F.

Breast. 2018 Aug 4;41:165-171. doi: 10.1016/j.breast.2018.08.002. [Epub ahead of print]

PMID:
30103105
2.

Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota.

Morgillo F, Dallio M, Della Corte CM, Gravina AG, Viscardi G, Loguercio C, Ciardiello F, Federico A.

Neoplasia. 2018 Jul;20(7):721-733. doi: 10.1016/j.neo.2018.05.002. Epub 2018 May 30. Review. No abstract available.

3.

Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells.

Ciaramella V, Della Corte CM, Di Mauro C, Tomassi S, Di Maro S, Troiani T, Martinelli E, Bianco R, Cosconati S, Pierantoni R, Meccariello R, Chianese R, Ciardiello F, Morgillo F.

Oncotarget. 2018 Apr 10;9(27):19273-19282. doi: 10.18632/oncotarget.25018. eCollection 2018 Apr 10.

4.

Kisspeptin and Cancer: Molecular Interaction, Biological Functions, and Future Perspectives.

Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F.

Front Endocrinol (Lausanne). 2018 Mar 27;9:115. doi: 10.3389/fendo.2018.00115. eCollection 2018. Review.

5.

Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Della Corte CM, Ciaramella V, Cardone C, La Monica S, Alfieri R, Petronini PG, Malapelle U, Vigliar E, Pepe F, Troncone G, Castellone MD, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

J Thorac Oncol. 2018 Jun;13(6):810-820. doi: 10.1016/j.jtho.2018.02.025. Epub 2018 Mar 8.

PMID:
29526823
6.

Role and targeting of anaplastic lymphoma kinase in cancer.

Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F.

Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. Review.

7.

Primary pleural squamous cell carcinoma: A diagnostic challenge.

Ronchi A, Cozzolino I, Montella M, Vicidomini G, Morgillo F, Della Corte CM, Franco R, Accardo M.

Cytopathology. 2018 Apr;29(2):205-207. doi: 10.1111/cyt.12498. Epub 2017 Nov 21. No abstract available.

PMID:
29159961
8.

Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFR-dependent and in cetuximab-resistant human colorectal cancer cells.

Napolitano S, Martini G, Martinelli E, Della Corte CM, Morgillo F, Belli V, Cardone C, Matrone N, Ciardiello F, Troiani T.

Oncotarget. 2017 Aug 2;8(47):82773-82783. doi: 10.18632/oncotarget.19797. eCollection 2017 Oct 10.

9.

Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.

Morgillo F, Della Corte CM, Diana A, Mauro CD, Ciaramella V, Barra G, Belli V, Franzese E, Bianco R, Maiello E, de Vita F, Ciardiello F, Orditura M.

Oncotarget. 2017 Aug 22;8(44):76479-76491. doi: 10.18632/oncotarget.20385. eCollection 2017 Sep 29.

10.

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Morgillo F, Amendola G, Della Corte CM, Giacomelli C, Botta L, Di Maro S, Messere A, Ciaramella V, Taliani S, Marinelli L, Trincavelli ML, Martini C, Novellino E, Ciardiello F, Cosconati S.

J Med Chem. 2017 Sep 14;60(17):7447-7458. doi: 10.1021/acs.jmedchem.7b00794. Epub 2017 Aug 22.

PMID:
28787156
11.

Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.

Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E.

World J Gastroenterol. 2017 Jul 14;23(26):4675-4688. doi: 10.3748/wjg.v23.i26.4675. Review.

12.

Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.

Morgillo F, Fasano M, Della Corte CM, Sasso FC, Papaccio F, Viscardi G, Esposito G, Di Liello R, Normanno N, Capuano A, Berrino L, Vicidomini G, Fiorelli A, Santini M, Ciardiello F.

ESMO Open. 2017 May 2;2(2):e000132. doi: 10.1136/esmoopen-2016-000132. eCollection 2017.

13.

Implication of the Hedgehog pathway in hepatocellular carcinoma.

Della Corte CM, Viscardi G, Papaccio F, Esposito G, Martini G, Ciardiello D, Martinelli E, Ciardiello F, Morgillo F.

World J Gastroenterol. 2017 Jun 28;23(24):4330-4340. doi: 10.3748/wjg.v23.i24.4330. Review.

14.

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.

Della Corte CM, Malapelle U, Vigliar E, Pepe F, Troncone G, Ciaramella V, Troiani T, Martinelli E, Belli V, Ciardiello F, Morgillo F.

Oncotarget. 2017 Apr 4;8(14):23020-23032. doi: 10.18632/oncotarget.15479.

15.

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review.

Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F.

Oncol Lett. 2016 Dec;12(6):4505-4509. doi: 10.3892/ol.2016.5279. Epub 2016 Oct 18.

16.

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Troiani T, Napolitano S, Della Corte CM, Martini G, Martinelli E, Morgillo F, Ciardiello F.

ESMO Open. 2016 Sep 16;1(5):e000088. eCollection 2016. Review.

17.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer.

Morgillo F, Della Corte CM, Fasano M, Ciardiello F.

ESMO Open. 2016 May 11;1(3):e000060. eCollection 2016. Review.

18.

Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.

Della Corte CM, Ciaramella V, Di Mauro C, Castellone MD, Papaccio F, Fasano M, Sasso FC, Martinelli E, Troiani T, De Vita F, Orditura M, Bianco R, Ciardiello F, Morgillo F.

Oncotarget. 2016 Jan 26;7(4):4265-78. doi: 10.18632/oncotarget.6559.

19.

SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.

Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.

Clin Cancer Res. 2015 Oct 15;21(20):4686-97. doi: 10.1158/1078-0432.CCR-14-3319. Epub 2015 Jun 29.

20.

Pulmonary Large-Cell Neuroendocrine Carcinoma: From Epidemiology to Therapy.

Fasano M, Della Corte CM, Papaccio F, Ciardiello F, Morgillo F.

J Thorac Oncol. 2015 Aug;10(8):1133-41. doi: 10.1097/JTO.0000000000000589.

21.

Vertebral carcinomatosis eleven years after advanced gastric cancer resection: A case report.

Iovino F, Orditura M, Auriemma PP, Ciorra FR, Giordano G, Orabona C, Bara F, Sergio R, Savastano B, Fabozzi A, Laterza MM, Ventriglia J, Petrillo A, Della Corte CM, DE Vita F.

Oncol Lett. 2015 Mar;9(3):1403-1405. Epub 2014 Dec 23.

22.

Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.

Della Corte CM, Fasano M, Papaccio F, Ciardiello F, Morgillo F.

Biomedicines. 2014 Nov 25;2(4):345-358. doi: 10.3390/biomedicines2040345. Review.

23.

A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.

Fasano M, Della Corte CM, Capuano A, Sasso FC, Papaccio F, Berrino L, Ciardiello F, Morgillo F.

Clin Lung Cancer. 2015 Jan;16(1):57-9. doi: 10.1016/j.cllc.2014.06.010. Epub 2014 Aug 17.

PMID:
25242667
24.

Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.

Fasano M, Della Corte CM, Califano R, Capuano A, Troiani T, Martinelli E, Ciardiello F, Morgillo F.

Expert Opin Investig Drugs. 2014 Jun;23(6):809-21. doi: 10.1517/13543784.2014.902934. Epub 2014 Mar 28. Review.

PMID:
24673358
25.

Metformin in lung cancer: rationale for a combination therapy.

Morgillo F, Sasso FC, Della Corte CM, Festino L, Manzo A, Martinelli E, Troiani T, Capuano A, Ciardiello F.

Expert Opin Investig Drugs. 2013 Nov;22(11):1401-9. doi: 10.1517/13543784.2013.828691. Epub 2013 Aug 12. Review.

PMID:
23937224
26.

Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.

Morgillo F, Sasso FC, Della Corte CM, Vitagliano D, D'Aiuto E, Troiani T, Martinelli E, De Vita F, Orditura M, De Palma R, Ciardiello F.

Clin Cancer Res. 2013 Jul 1;19(13):3508-19. doi: 10.1158/1078-0432.CCR-12-2777. Epub 2013 May 21.

Supplemental Content

Loading ...
Support Center